文献速递认知障碍与痴呆神经免疫

多发性硬化灰质萎缩模式与临床表型及进展的关联

Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.
PubMed 文献 · Neurology · 2021-01-13

研究基于8个欧洲中心的170名健康对照和398例多发性硬化患者,采用基于源的形态学分析灰质萎缩及其1年演变。结果显示不同表型的灰质萎缩模式存在差异,基线整体灰质体积与小脑灰质萎缩可独立预测1年临床恶化。

要点

  • 不同多发性硬化表型的灰质萎缩空间模式存在差异
  • 基线小脑灰质萎缩独立预测1年临床恶化
  • 感觉运动与小脑灰质萎缩可解释基线残疾水平

核心结论

  • 多发性硬化灰质萎缩随疾病表型不同而不同,并在1年内进展
  • 除整体萎缩指标外,感觉运动和小脑灰质萎缩可解释基线残疾与临床恶化

研究设计与样本

  • 多中心研究,纳入8个欧洲中心的170名健康对照和398例多发性硬化患者
  • 患者包括34例临床孤立综合征、226例复发缓解型、95例继发进展型和43例原发进展型

主要发现

  • 基于源的形态学识别出26个涉及小脑、皮层下、感觉运动与认知的灰质成分
  • 多发性硬化患者几乎在所有成分上均较健康对照存在灰质萎缩(p范围<0.001-0.04)
  • 临床孤立综合征患者呈局限性皮层下、小脑、颞叶及突显网络灰质萎缩,复发缓解型患者呈广泛灰质萎缩
  • 原发进展型较健康对照、继发进展型较复发缓解型均存在小脑、皮层下、感觉运动、突显网络及额顶叶灰质萎缩
  • 1年时21例(15%)患者临床恶化,灰质萎缩在皮层下、小脑、感觉运动及额-颞-顶叶成分进展

临床怎么用

  • 可将灰质萎缩模式用于辅助区分多发性硬化表型
  • 基线小脑灰质萎缩与整体灰质体积可帮助识别1年内临床恶化风险较高的患者

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Gay matter (GM) involvement is clinically relevant in multiple sclerosis (MS). Using source-based morphometry (SBM), we characterized GM atrophy and its 1-year evolution across different MS phenotypes. METHODS: Clinical and MRI data were obtained at 8 European sites from 170 healthy controls (HCs) and 398 patients with MS (34 with clinically isolated syndrome [CIS], 226 with relapsing-remitting MS [RRMS], 95 with secondary progressive MS [SPMS], and 43 with primary progressive MS [PPMS]). Fifty-seven HCs and 144 with MS underwent 1-year follow-up. Baseline GM loss, atrophy progression, and correlations with disability and 1-year clinical worsening were assessed. RESULTS: SBM identified 26 cerebellar, subcortical, sensory, motor, and cognitive GM components. GM atrophy was found in patients with MS vs HCs in almost all components (p range <0.001-0.04). Compared to HCs, patients with CIS showed circumscribed subcortical, cerebellar, temporal, and salience GM atrophy, while patients with RRMS exhibited widespread GM atrophy. Cerebellar, subcortical, sensorimotor, salience, and frontoparietal GM atrophy was found in patients with PPMS vs HCs and in patients with SPMS vs those with RRMS. At 1 year, 21 (15%) patients had clinically worsened. GM atrophy progressed in MS in subcortical, cerebellar, sensorimotor, and fronto-temporo-parietal components. Baseline higher disability was associated (R 2 = 0.65) with baseline lower normalized brain volume (β = -0.13, p = 0.001), greater sensorimotor GM atrophy (β = -0.12, p = 0.002), and longer disease duration (β = 0.09, p = 0.04). Baseline normalized GM volume (odds ratio 0.98, p = 0.008) and cerebellar GM atrophy (odds ratio 0.40, p = 0.01) independently predicted clinical worsening (area under the curve 0.83). CONCLUSION: GM atrophy differed across disease phenotypes and progressed at 1 year in MS. In addition to global atrophy measures, sensorimotor and cerebellar GM atrophy explained baseline disability and clinical worsening.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Rocca MA, Valsasina P, Meani A, et al. Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. Neurology. 2021. PMID: 33441452. doi:10.1212/WNL.0000000000011494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。